Kura Oncology Inc (NASDAQ:KURA) – Equities research analysts at Piper Jaffray Companies lowered their FY2023 earnings estimates for Kura Oncology in a report released on Thursday, August 1st. Piper Jaffray Companies analyst T. Van. Buren now expects that the company will post earnings per share of $0.30 for the year, down from their previous estimate of $0.35.
Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.03.
NASDAQ KURA opened at $18.89 on Monday. The business’s 50-day moving average is $19.60. The company has a debt-to-equity ratio of 0.03, a quick ratio of 23.50 and a current ratio of 23.50. Kura Oncology has a 1 year low of $10.20 and a 1 year high of $21.70.
Large investors have recently added to or reduced their stakes in the business. CWM LLC purchased a new position in Kura Oncology during the 1st quarter valued at about $25,000. Meeder Asset Management Inc. grew its stake in Kura Oncology by 164.9% during the 2nd quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after acquiring an additional 1,204 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Kura Oncology by 599.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after acquiring an additional 2,420 shares in the last quarter. Legacy Advisors LLC purchased a new position in Kura Oncology during the 1st quarter valued at about $65,000. Finally, Great West Life Assurance Co. Can purchased a new position in Kura Oncology during the 4th quarter valued at about $62,000. 83.82% of the stock is currently owned by institutional investors.
In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of Kura Oncology stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $21.11, for a total transaction of $379,980.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 11.00% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Recommended Story: The benefits and drawbacks of dollar cost averaging
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.